Form 8-K - Current report:
SEC Accession No. 0001193125-25-138813
Filing Date
2025-06-11
Accepted
2025-06-11 08:15:24
Documents
14
Period of Report
2025-06-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d21181d8k.htm   iXBRL 8-K 29701
2 EX-99.1 d21181dex991.htm EX-99.1 11316
6 GRAPHIC g21181g0611045719636.jpg GRAPHIC 2734
  Complete submission text file 0001193125-25-138813.txt   165893

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cogt-20250611.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20250611_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20250611_pre.xml EX-101.PRE 11265
16 EXTRACTED XBRL INSTANCE DOCUMENT d21181d8k_htm.xml XML 3625
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 251038824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)